HOME >> BIOLOGY >> NEWS
Pharmaceutical 'smart bomb' targets cancer cells

even in cancer cells is used as the activator. When researchers insert a gene for this enzyme into cancer cells, the cells start to express the nitroreductase, making them an easy target. The prodrug "bomb" goes off and unleashes the toxin that spreads to neighboring cells which ultimately kills the tumor.

The English contingent also developed a compound that is being evaluated in clinical trials as an anticancer prodrug. But Hu's new compounds appear to be even more potent. The overseas researchers are now testing the Rutgers compounds, side by side with their own, delivering them in the enhanced prodrug packages.

Initial testing on mammalian hamster cells shows that after 72 hours of drug exposure, the Rutgers compounds were as much as 100 times more effective in inhibiting cell growth. One-hour tests were also performed and, again, the Rutgers compounds were found to be superior as much as 30 times more effective than the English compound. Eighteen-hour tests on human ovarian cancer cells showed a still significant, tenfold superiority.

"Our cytotoxic compounds delivered to the cancer site in a revamped prodrug form clearly show great potential, but there are still lots of tests to be done," said Hu. "There are many preclinical studies ahead of us. If everything goes well, we could see clinical trials in humans in a couple of years."

Hu says that these compounds are not going to cure cancer by themselves. But they will be significant tools, most probably used in combination with other technologies one bullet of many in the arsenal of anticancer weapons.


'"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 Ext. 652
Rutgers, the State University of New Jersey
31-Dec-2000


Page: 1 2

Related biology news :

1. Warren Pharmaceuticals publishes results of preclinical evaluation
2. Cyclis Pharmaceuticals reports studies defining new mechanism for potential cancer therapies
3. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
4. Pharmaceutical and personal care products: What happens when they enter the environment - an emerging concern
5. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
6. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
7. Idun Pharmaceuticals Identifies Cell Type And Molecular Pathway Involved In TransplantationRelated Liver Damage
8. Cubist Pharmaceuticals Describes New VITA™ Technology For Enabling Genomics For Drug Discovery
9. Vertex Pharmaceuticals/Yale Research Team Uses Gene Knockout Mice To Establish Role Of Caspase-9 In Neuronal Cell Death Pathway
10. Micro-Plants Yield Pharmaceutical New Wave
11. Scientists At The Scripps Research Institute And R.W. Johnson Pharmaceuticals Develop New Antibacterial Agents

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/5/2018)... , ... October 04, 2018 , ... EDETEK, the premier ... at the CDISC U.S. Interchange in Bethesda, MD on October 8-12, 2018. EDETEK is ... City, CA on November 5-6, 2018. , CDISC Interchanges are global events held ...
(Date:10/3/2018)... (PRWEB) , ... October 03, ... ... company focused on the discovery, development and commercialization of first-in-class stromal cell ... being administered to patients with type 2 diabetes and progressive diabetic kidney ...
(Date:10/2/2018)... ... October 02, 2018 , ... The Federal Identity ... at Tampa Convention Center. The Palo Alto-based face recognition company, Camvi Technologies Inc., ... 27th. Other speakers included U.S. Federal executives from Department of Defense (DoD) and ...
Breaking Biology News(10 mins):
(Date:9/27/2018)... (PRWEB) , ... September 27, 2018 , ... ... offices in Cambridge, MA, announce today that Holotype HLA and other Omixon products ... annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in Baltimore, ...
(Date:9/22/2018)... ... 2018 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it will be co-hosting a workshop with BASF Corporation ... one-day event is to be held at the Hilton Boston Back Bay hotel, ...
(Date:9/15/2018)... , ... September 14, 2018 , ... Nationally recognized public ... G. Patrick, CPA , Managing Partner of the Firm’s Nashville practice, on her appointment ... Bekaert since 2009 and was named Managing Partner of the Firm’s Nashville practice ...
(Date:9/12/2018)... ... September 11, 2018 , ... ... American Association of Feline Practitioners Conference (AAFP) later this month. ... adipose-derived stem cell therapy for the treatment of chronic kidney disease in felines ...
Breaking Biology Technology:
Cached News: